Alexis Littre (17 July 1654 – 3 February 1726) was a French physician and anatomist born in Cordes (currently Cordes-Tolosannes in the department of Tarn-et-Garonne). Biography
Littre studied medicine in Montpellier and Paris, receiving his doctorate in 1691. In 1699 he became a member of the Académie des Sciences. In Paris, he taught anatomy and was the author of numerous medical publications. He was the first to give a description of a hernial protrusion of an intestinal diverticulum. This condition is now referred to as "Littres hernia".He also described the mucous urethral glands of the male urethra. These structures were to become known as "Littres glands", and their inflammation is sometimes called "littreitis".In his 1710 treatise Diverses observations anatomiques, Littre was the first to suggest the possibility of performing a lumbar colostomy for an obstruction of the colon.Jean Louis Petit was one of his students. So was Jacques-Bénigne Winslow in 1707. He died in Paris. References
Alexis de Littre @ Who Named It

Notes
External links
Online articles by Littré 10 articles (2012-05-15) on the site of the Académie des sciences. Cotlar, Alvin M. (January 2002). "Historical landmarks in operations on the colon—surgeons courageous". Current Surgery. Elsevier. 59 (1): 91–95. doi:10.1016/s0149-7944(01)00606-7. ISSN 0149-7944. PMID 16093113. Bernard Le Bovier de Fontenelle, Éloge de Monsieur Littré, p. 129, at Google Books, 1754, p. 129 (Eulogy)
To minimize the risk of CRS and to offset some of the minor side effects patient experience, glucocorticoids (such as methylprednisolone), acetaminophen, and diphenhydramine are given before the infusion.Other adverse effects include leucopenia, as well as an increased risk for severe infections and malignancies typical of immunosuppressive therapies. Neurological side effects like aseptic meningitis and encephalopathy have been observed. Possibly, they are also caused by the T cell activation.Repeated application can result in tachyphylaxis (reduced effectiveness) due to the formation of anti-mouse antibodies in the patient, which accelerates elimination of the drug. It can also lead to an anaphylactic reaction against the mouse protein, which may be difficult to distinguish from a CRS. Contraindications
Except under special circumstances, the drug is contraindicated for patients with an allergy against mouse proteins, as well as patients with uncompensated heart failure, uncontrolled arterial hypertension or epilepsy. It should not be used during pregnancy or lactation. Etymology
Muromonab-CD3 was developed before the WHO nomenclature of monoclonal antibodies took effect, and consequently its name does not follow this convention. Instead, it is a contraction from "murine monoclonal antibody targeting CD3". == References ==